Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies. This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204) ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.Ī Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers Patients with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible. This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER+ and/or PR+ cancers. Treatment study for people with advanced breast, endometrial or ovarian cancer. Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with anĪdvanced solid tumor with either an inherited or tumor PALB2 mutation. PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)Īny advanced or metastatic solid tumor except ovarian or prostate This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy. Treatment study for people with advanced cancers Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors Participants will be placed into study groups based on their tumor. This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.
KEYNOTE 158 CLINICAL TRIALS.GOV FREE
The study is being conducted to determine if pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).Ī Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. This study is used to test the safety and effectiveness of using an immunotherapy treatment in patients with advanced tumors.Ĭomparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer This study will test the safety and effectiveness of using an immunotherapy treatment in patients with advanced tumors. : Treatment + Endometrial Cancer (11 results) Study of an Immunotherapy Treatment in Individuals with Advanced or Metastatic Solid Tumors
0 kommentar(er)
